TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated acute myeloid leukemia
Schurer, A.; Ilyas, H.; Maron, M. I.; Hegde, S.; Leyden, M. R.; Roy, I.; Hyka, R.; Dada, L.; Shabanowitz, J.; Hunt, D.; Angeles, E.; Morell, V.; Lorton, B. M.; Glushakow-Smith, S.; Borger, D. K.; Wang, Y.; Miles, L. A.; Belizaire, R.; Kitamura, S.; Gritsman, K.; Shechter, D.
Show abstract
NPM1-mutated acute myeloid leukemia (AML) is defined by aberrant cytoplasmic localization of the mutant NPM1c protein, and therapeutic strategies targeting this specific disease remain limited. Here, we identify TTLL4, a mono-glutamate glutamyltransferase, as a selective vulnerability in NPM1c AML. TTLL4 catalyzes post-translational hyper-glutamylation of NPM1c at E126, stabilizes its cytoplasmic localization and promotes a differentiation block in leukemic cells. Multiple genetic TTLL4 inactivation approaches in human NPM1c-mutant cell lines reduce NPM1c glutamylation, trigger myeloid differentiation, and impair proliferation. Transcriptomic analyses show that TTLL4 knockdown pheno-copies NPM1c degradation and aligns with KMT2A and XPO1-targeted gene expression programs. Furthermore, Ttll4 knockout significantly prolonged survival in an NPM1c/NRAS-driven mouse AML model and promoted differentiation. We identify a small molecule, EN7, that selectively inhibits TTLL4 and recapitulates these phenotypes in NPM1c+ cells. These findings identify glutamylation as a new axis of leukemic regulation and highlight TTLL4 as a druggable epigenetic regulator in NPM1c AML.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Mutant-SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms 97%
- MondoA Drives Malignancy in cALL through Enhanced Adaptation to Metabolic Stress 96%
- BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor 96%
Similar papers in this journal
Similar papers in this journal
- AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML 97%
- Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network 96%
- Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewal. 95%
Similar papers in this journal
- Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia 97%
- Reprogramming of serine metabolism is an actionable vulnerability in FLT3-ITD driven acute myeloid leukaemia 97%
- An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML 97%
Similar papers in this journal
- Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia 97%
- Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia 96%
- Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.